About
Nabla, founded in 2018 in Boston, Massachusetts, USA, provides AI assistants for healthcare practitioners that rapidly generate clinical notes across specialties, reducing clinician workload and improving patient care quality.
Full tier & rationale — an SVTR Intelligence benefit
Timeline
- 2025-06FundingC轮$70M
- 2024-05FundingA轮$26M
- 2024-01FundingNew funding round$24M
Public events aggregated from this page; rating changes are member-only.
Capital graph
Founders / core team
Investors
Funding history
- 2025-06Series C$70M
Investors · HV Capital、Build Collective、DST Global、Cathay、Highland Europe
Source · SVTR Weekly #110 - 2024-05Series A$26M
Investors · Radical Ventures
Source · SVTR Weekly #053 - 2024-01$24M
Investors · Cathay、Zebox Ventures
Source · SVTR Weekly #034
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Nabla
Nabla, founded in 2018 in Boston, Massachusetts, USA, provides AI assistants for healthcare practitioners that rapidly generate clinical notes across specialties, reducing clinician workload and improving patient care quality.
Series C · $120M · 2025-06
$120M
United States
BusinessLatest roundTotal raisedDate- Suki
Suki, founded in 2020 in California, USA, develops AI-powered voice assistants that help physicians handle tasks such as medical documentation and clinical notes. The company has partnered with over 300 healthcare systems and integrates with Epic, Oracle's Cerner, Athena, and MEDITECH.
Series D+ · $250M · 2026-10
$250M - Xellar Biosystems
Yaoso Technology is a biopharma R&D platform company centered on organ-on-a-chip technology, integrating high-content 3D cell imaging, computer vision, AI, and high-throughput automation. It has built a 3D Bio Intelligence system serving drug discovery and precision medicine, with partnerships including Sanofi.
Series A · $63M · 2026-06
$63M - Akido Labs
Akido Labs, founded in 2015 in Los Angeles, USA, develops AI tools to assist healthcare providers, covering functions such as generating clinical questions, documenting patient responses, and optimizing medical workflows.
Series B · $60M · 2025-05
$60M
China
BusinessLatest roundTotal raisedDate- Drug Farm
Innovative-drug developer using genetics and AI to discover first-in-class targets
Series D+ · $55M · 2026-07
$55M - Insilico Medicine
Insilico Medicine, founded in 2019 in Shanghai, China, is a developer of drug candidates for anti-aging and cancer treatment.
Series D+ · $210M · 2025-03
$210M - Deep Pharma
Deep Intelligent Pharma (DIP), founded in 2017 in Beijing, China, is an AI-driven drug discovery and clinical development platform with a multi-agent system.
Series D+ · $200M · 2026-03
$200M
Europe
BusinessLatest roundTotal raisedDate- Tandem Health
Tandem Health, founded in 2023 in Sweden, develops AI-powered software that helps healthcare providers by automatically generating medical records. The platform leverages GPT-4 and OpenAI's Whisper speech recognition technology, with adaptations for Swedish medical terminology.
Series B · $160M · 2026-09
$160M - Voize
Voize, founded in 2020 in Potsdam, Germany, provides an AI-powered mobile app that enables care workers to document patient information via voice input, automatically generating structured reports.
Series A · $59M · 2025-11
$59M - Aqemia
Aqemia, founded in 2019 in Paris, France, uses generative AI and quantum physics to discover cancer drugs, differentiating itself by not requiring experimental chemistry data to train its models during the design phase.
Undisclosed · $71M · 2024-12
$71M
Other / unspecified
BusinessLatest roundTotal raisedDate- Reliant AI
Reliant AI, founded in 2023 and headquartered in Montreal, Canada and Berlin, Germany, uses generative AI to help biopharmaceutical companies organize and analyze large volumes of complex data for use cases such as clinical trials and scientific publications.
Seed · $11M · 2024-08
$11M - Heidi Health
Heidi Health (formerly Oscer), founded in 2019 in Melbourne, Australia, reduces administrative burden on physicians by using AI to convert consultation recordings into medical histories, referral letters, billing forms, and other clinical documents.
Series C · $437M · 2026-09 · Valuation $900M
$437MValuation $900M - Lumonus AI
Lumonus AI, founded in 2022 in Sydney, Australia, automates workflow and knowledge management for radiation oncology departments through its AI Physician platform.
Series B · $16M · 2025-11
$16M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
39 Life Sciences deals in the last 24 months · 14 at a nearby stage · 35 in Boston Metro
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 10 at a nearby stage · 31 in Boston Metro
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 12 at a nearby stage · 22 in Boston Metro
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 10 at a nearby stage · 20 in Boston Metro
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 11 at a nearby stage · 15 in Boston Metro
Request intro →Lightspeed
16 Life Sciences deals in the last 24 months · 11 at a nearby stage · 14 in Boston Metro
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.